浏览全部资源
扫码关注微信
有氧糖酵解在肝癌中的研究进展
Research progress of aerobic glycolysis in liver cancer
- 局解手术学杂志 2024年33卷第11期 页码：963-966
- 作者机构：
1.山东省淄博市周村区人民医院普通外科，山东 淄博 255399
2.重庆医科大学附属第三医院肝胆胰外科，重庆 401120
- 作者简介：
张治清，E-mail：340157332@qq.com
- 基金信息：重庆市自然科学基金(cstc2020jcjy-msxmX0565)
DOI：10.11659/jjssx.08E023056
中图分类号： R735.7纸质出版日期：2024-11-25，
收稿日期：2023-08-15，
- 稿件说明：
移动端阅览
王强,张治清.有氧糖酵解在肝癌中的研究进展[J].局解手术学杂志,2024,33(11):963-966.
WANG Qiang,ZHANG Zhi-qing.Research progress of aerobic glycolysis in liver cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):963-966.
王强,张治清.有氧糖酵解在肝癌中的研究进展[J].局解手术学杂志,2024,33(11):963-966. DOI： 10.11659/jjssx.08E023056.
WANG Qiang,ZHANG Zhi-qing.Research progress of aerobic glycolysis in liver cancer[J].JOURNAL OF REGIONAL ANATOMY AND OPERATIVE SURGERY,2024,33(11):963-966. DOI： 10.11659/jjssx.08E023056.
摘要
肝癌的发病率及病死率居全球恶性肿瘤的第5位和第3位，其中肝细胞癌(HCC)占原发性肝癌的90%。有氧糖酵解首次在HCC中被发现，作为肝癌细胞能量代谢的标志，可调节细胞增殖、免疫逃逸、侵袭、转移及耐药等。糖酵解主要有3个限速酶，即磷酸果糖激酶1(PFK-1)、丙酮酸激酶M2(PKM2)和己糖激酶2(HK2)，这些限速酶在糖酵解过程中发挥着重要作用，并受到多种机制调控。有氧糖酵解在HCC发生发展中具有重要作用，靶向阻断其通路中的关键因子，可成为肝癌的潜在治疗措施。随着有氧糖酵解关键酶激动/抑制剂的发展，其靶向治疗的前景值得期待。因此，本文对肝癌有氧糖酵解的研究进展作一综述，总结有氧糖酵解在肝癌发展及治疗中的作用，以期为临床提供参考。
Abstract
Liver cancer has the fifth morbidity and the third mortality among maligant tumors in the worldwide，and hepatocellular carcinoma （HCC） accounts for 90% of primary liver cancer. Aerobic glycolysis，as a hallmark of hepatoma cell energy metabolism，is firstly found in HCC and responsible for the regulation of cell proliferation，immune evasion，invasion，metastasis，and drug resistance. There are three rate-limiting enzymes in the glycolysis，including phosphofructokinase 1 （PFK1），pyruvate kinases type M2 （PKM2） and hexokinase 2 （HK2），which play an important role in the regulation of aerobic glycolysis and can be regulated by many mechanisms. Because of the importance of aerobic glycolysis in the occurrence and development of HCC，targeting and blocking key factors in its pathway may be a potential therapeutic treatment for HCC. With the development of key enzymes activations/inhibitors of aerobic glycolysis，the prospect of targeted therapy should be expected. Therefore，this article reviews the research progress of aerobic glycolysis in liver cancer，and summarize the role of aerobic glycolysis in the development and treatment of liver cancer，in order to provide clinical reference.
关键词
有氧糖酵解关键酶肝细胞癌己糖激酶Warburg效应丙酮酸激酶
Keywords
aerobic glycolysiskey enzymeshepatocellular carcinomahexokinaseWarburg effectpyruvate kinases
references
Feng J，Li JJ，Wu LW，et al. Emerging roles and the regulation of aerobic glycolysis in hepatocellular carcinoma［J］. J Exp Clin Cancer Res，2020，39（1）：126. doi：10.1186/s13046-020-01629-4http://dx.doi.org/10.1186/s13046-020-01629-4.
Xu Y，Hao X，Ren Y， et al. Research progress of abnormal lactate metabolism and lactate modification in immunotherapy of hepatocellular carcinoma［J］.Front Oncol，2022，12：1063423.doi：10.3389/fonc.2022.1063423http://dx.doi.org/10.3389/fonc.2022.1063423.
Xia C，Dong X，Li H，et al. Cancer statistics in China and United States，2022：profiles，trends，and determinants［J］. Chin Med J （Engl），2022，135（5）：584-590.doi： 10.1097/CM9.0000000000002108http://dx.doi.org/10.1097/CM9.0000000000002108.
El Kassas M，Tawheed A，Eltabbakh M，et al.Hepatitis C antiviral therapy in patients with successfully treated hepatocellular carcinoma：dancing with wolves［J］. J Hepatocell Carcinoma，2019，6：183-191.doi： 10.2147/JHC.S206668http://dx.doi.org/10.2147/JHC.S206668.
Matsumoto K，Noda T，Kobayashi S， et al. Inhibition of glycolytic activator PFKFB3 suppresses tumor growth and induces tumor vessel normalization in hepatocellular carcinoma［J］. Cancer Lett，2021，500：29-40. doi： 10.1016/j.canlet.2020.12.011http://dx.doi.org/10.1016/j.canlet.2020.12.011.
Yalcin A，Solakoglu TH，Ozcan SC，et al. 6-phosphofructo-2-kinase/fructose 2，6-bisphosphatase-3 is required for transforming growth factor beta1-enhanced invasion of Panc1 cells in vitro［J］. Biochem Biophys Res Commun，2017，484（3）：687-693. doi： 10.1016/j.bbrc.2017.01.178http://dx.doi.org/10.1016/j.bbrc.2017.01.178.
St-Gallay SA，Bennett N，Critchlow SE，et al. A high-throughput screening triage workflow to authenticate a novel series of PFKFB3 inhibitors［J］.SLAS Discov，2018，23（1）：11-22.doi：10.1177/2472555217732289http://dx.doi.org/10.1177/2472555217732289.
DeWaal D，Nogueira V，Terry AR，et al. Hexokinase-2 depletion inhibits glycolysis and induces oxidative phosphorylation in hepatocellular carcinoma and sensitizes to metformin［J］. Nat Commun，2018，9（1）：446. doi： 10.1038/s41467-018-04182-zhttp://dx.doi.org/10.1038/s41467-018-04182-z.
Xu S，Catapang A，Doh HM，et al. Hexokinase 2 is targetable for HK1 negative，HK2 positive tumors from a wide variety of tissues of origin［J］.J Nucl Med，2018，60（2）：212-217.doi：10.2967/jnumed.118.212365http://dx.doi.org/10.2967/jnumed.118.212365.
Guzman G，Chennuri R，Chan A，et al. Evidence for heightened hexokinase Ⅱ immunoexpression in hepatocyte dysplasia and hepatocellular carcinoma［J］. Dig Dis Sci，2015，60（2）：420-426. doi： 10.1007/s10620-014-3364-3http://dx.doi.org/10.1007/s10620-014-3364-3.
Niu Y，Liu F，Wang X，et al. miR-183-5p promotes HCC migration/invasion via increasing aerobic glycolysis［J］. Onco Targets Ther，2021，14：3649-3658.doi：10.2147/OTT.S304117http://dx.doi.org/10.2147/OTT.S304117.
Jiao L，Zhang HL，Li DD， et al. Regulation of glycolytic metabolism by autophagy in liver cancer involves selective autophagic degradation of HK2 （hexokinase 2）［J］. Autophagy，2018，14（4）：671-684.doi： 10.1080/15548627.2017.1381804http://dx.doi.org/10.1080/15548627.2017.1381804.
Jones BC，Pohlmann PR，Clarke R，et al. Treatment against glucose-dependent cancers through metabolic PFKFB3 targeting of glycolytic flux［J］. Cancer Metastasis Rev，2022，41（2）：447-458. doi： 10.1007/s10555-022-10027-5http://dx.doi.org/10.1007/s10555-022-10027-5.
Reyes Serratos EA，Fernandez Castillo E，Sanchez Lopez L，et al. Down regulation of tumour biomarkers in colon cancer cells with IRNA PFK-1 plus metformin［J］. J BUON，2021，26（4）：1210-1218.
Kotowski K，Rosik J，Machaj F，et al.Role of PFKFB3 and PFKFB4 in cancer：genetic basis，impact on disease development/progression，and potential as therapeutic targets［J］. Cancers （Basel），2021，13（4）：909. doi：10.3390/cancers13040909http://dx.doi.org/10.3390/cancers13040909.
Shi L，Pan H，Liu Z，et al.Roles of PFKFB3 in cancer［J］.Signal Transduct Target Ther，2017，2：17044.doi：10.1038/sigtrans.2017.44http://dx.doi.org/10.1038/sigtrans.2017.44.
Zeng L，Zhou KX，Yang H，et al.TRIM28 regulates hepatocellular carcinoma progression and aerobic glycolysis through interacting with PFKFB3［J］.J Biol Regul Homeost Agents，2023，37（2）：951-959.doi：10.23812/j.biol.regul.homeost.agents.20233702.97http://dx.doi.org/10.23812/j.biol.regul.homeost.agents.20233702.97.
Li F，Huangyang P，Burrows M，et al. FBP1 loss disrupts liver metabolism and promotes tumorigenesis through a hepatic stellate cell senescence secretome［J］. Nat Cell Biol，2020，22（6）：728-739. doi：10.1038/s41556-020-0511-2http://dx.doi.org/10.1038/s41556-020-0511-2.
Du D，Liu C，Qin M，et al. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma［J］. Acta Pharm Sin B，2022，12（2）：558-580.doi： 10.1016/j.apsb.2021.09.019http://dx.doi.org/10.1016/j.apsb.2021.09.019.
Peng ZP，Jiang ZZ，Guo HF，et al. Glycolytic activation of monocytes regulates the accumulation and function of neutrophils in human hepatocellular carcinoma［J］. J Hepatol，2020，73（4）：906-917. doi： 10.1016/j.jhep.2020.05.004http://dx.doi.org/10.1016/j.jhep.2020.05.004.
Shi WK，Zhu XD，Wang CH，et al. PFKFB3 blockade inhibits hepatocellular carcinoma growth by impairing DNA repair through AKT［J］. Cell Death Dis，2018，9（4）：428.doi：10.1038/s41419-018-0435-yhttp://dx.doi.org/10.1038/s41419-018-0435-y.
Vandekeere S，Dewerchin M，Carmeliet P.Angiogenesis revisited：an overlooked role of endothelial cell metabolism in vessel sprouting［J］. Microcirculation，2015，22（7）：509-517. doi：10.1111/micc.12229http://dx.doi.org/10.1111/micc.12229.
Abdi S，Montazeri V，Garjani A，et al. Coenzyme Q10 in association with metabolism-related AMPK/PFKFB3 and angiogenic VEGF/VEGFR2 genes in breast cancer patients［J］. Mol Biol Rep，2020，47（4）：2459-2473. doi：10.1007/s11033-020-05310-zhttp://dx.doi.org/10.1007/s11033-020-05310-z.
Chesney JA，Mitchell RA，Yaddanapudi K.Myeloid-derived suppressor cells-a new therapeutic target to overcome resistance to cancer immunotherapy［J］.J Leukoc Biol，2017，102（3）：727-740. doi： 10.1189/jlb.5VMR1116-458RRRhttp://dx.doi.org/10.1189/jlb.5VMR1116-458RRR.
Mondal S，Roy D，Sarkar Bhattacharya S，et al.Therapeutic targeting of PFKFB3 with a novel glycolytic inhibitor PFK158 promotes lipophagy and chemosensitivity in gynecologic cancers［J］. Int J Cancer，2019，144（1）：178-189.doi： 10.1002/ijc.32219http://dx.doi.org/10.1002/ijc.32219.
Chen DP，Ning WR，Jiang ZZ，et al. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma［J］. J Hepatol，2019，71（2）：333-343. doi： 10.1016/j.jhep.2019.04.007http://dx.doi.org/10.1016/j.jhep.2019.04.007.
Wiese EK，Hitosugi T. Tyrosine kinase signaling in cancer metabolism：PKM2 paradox in the Warburg effect［J］. Front Cell Dev Biol，2018，6：79.doi： 10.3389/fcell.2018.00079http://dx.doi.org/10.3389/fcell.2018.00079.
Chen L，Shi Y，Liu S，et al. PKM2：the thread linking energy metabolism reprogramming with epigenetics in cancer［J］. Int J Mol Sci，2014，15（7）：11435-11445. doi： 10.3390/ijms150711435http://dx.doi.org/10.3390/ijms150711435.
Gao F，Zhang X，Wang S，et al. TSP50 promotes the Warburg effect and hepatocyte proliferation via regulating PKM2 acetylation［J］. Cell Death Dis，2021，12（6）：517.doi：10.1038/s41419-021-03782-whttp://dx.doi.org/10.1038/s41419-021-03782-w.
Tamada M，Suematsu M，Saya H，et al. Pyruvate kinase M2：multiple faces for conferring benefits on cancer cells［J］. Clin Cancer Res，2012，18（20）：5554-5561.doi：10.1158/1078-0432.CCR-12-0859http://dx.doi.org/10.1158/1078-0432.CCR-12-0859.
van Niekerk G，Engelbrecht AM. Role of PKM2 in directing the metabolic fate of glucose in cancer：a potential therapeutic target［J］. Cell Oncol （Dordr），2018，41（4）：343-351.doi： 10.1007/s13402-018-0383-7http://dx.doi.org/10.1007/s13402-018-0383-7.
Yang W，Liu J，Hou L，et al. Shikonin differentially regulates glucose metabolism via PKM2 and HIF1alpha to overcome apoptosis in a refractory HCC cell line［J］.Life Sci，2021，265：118796.doi： 10.1016/j.lfs.2020.118796http://dx.doi.org/10.1016/j.lfs.2020.118796.
Yu Z，Wang D，Tang Y，et al. PKM2 promotes cell metastasis and inhibits autophagy via the JAK/STAT3 pathway in hepatocellular carcinoma［J］. Mol Cell Biochem，2021，476（5）：2001-2010. doi： 10.1007/s11010-020-04041-whttp://dx.doi.org/10.1007/s11010-020-04041-w.
Prakasam G，Iqbal MA，Bamezai RNK，et al. Posttranslational modifications of pyruvate kinase M2：tweaks that benefit cancer［J］. Front Oncol，2018，8：22. doi： 10.3389/fonc.2018.00022http://dx.doi.org/10.3389/fonc.2018.00022.
Israelsen WJ，Dayton TL，Davidson SM，et al. PKM2 isoform-specific deletion reveals a differential requirement for pyruvate kinase in tumor cells［J］.Cell，2013，155（2）：397-409.doi：10.1016/j.cell.2013.09.025http://dx.doi.org/10.1016/j.cell.2013.09.025.
Dayton TL，Gocheva V，Miller KM，et al. Germline loss of PKM2 promotes metabolic distress and hepatocellular carcinoma［J］. Genes Dev，2016，30（9）：1020-1033. doi： 10.1101/gad.278549.116http://dx.doi.org/10.1101/gad.278549.116.
Lu J，Liu SY，Zhang J，et al. Inhibition of BAG3 enhances the anticancer effect of shikonin in hepatocellular carcinoma［J］. Am J Cancer Res，2021，11（7）：3575-3593.
Siddiqui FA，Prakasam G，Chattopadhyay S，et al.Curcumin decreases Warburg effect in cancer cells by down-regulating pyruvate kinase M2 via mTOR-HIF1alpha inhibition［J］. Sci Rep，2018，8（1）：8323. doi： 10.1038/s41598-018-25524-3http://dx.doi.org/10.1038/s41598-018-25524-3.
Li W， Liu J， Zhao Y. PKM2 inhibitor shikonin suppresses TPA-induced mitochondrial malfunction and proliferation of skin epidermal JB6 cells［J］. Mol Carcinog，2014，53（5）：403-412.doi：10.1002/mc.21988http://dx.doi.org/10.1002/mc.21988.
Jiang Y，Wang Y，Wang T，et al. PKM2 phosphorylates MLC2 and regulates cytokinesis of tumour cells［J］. Nat Commun，2014，5：5566. doi： 10.1038/ncomms6566http://dx.doi.org/10.1038/ncomms6566.
Hosios AM，Fiske BP，Gui DY，et al. Lack of evidence for PKM2 protein kinase activity［J］. Mol Cell，2015，59（5）：850-857. doi： 10.1016/j.molcel.2015.07.013http://dx.doi.org/10.1016/j.molcel.2015.07.013.
0
浏览量
1
下载量
0
CSCD
- 网络PDF下载
- WORD下载
- Meta-XML下载
- BibTeX下载
- Endnote下载
- RefMan 下载
- NoteExpress下载
- NoteFirst下载
关联资源
相关文章
相关作者
相关机构
- 技术支持由北京北大方正电子有限公司提供 京ICP备09064830号-19
京公网安备11010802024621 - 本系统建议在Chrome、 IE9+ 以上版本浏览器阅读本站内容，360浏览器请切换至极速模式
- Cookies帮助我们提供服务并提供个性化体验。使用本网站，即表示您同意我们使用Cookies
